We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
Read MoreHide Full Article
Key Takeaways
Liquidia's Q3 revenues surged 314.6% to $225.3M, while YUTREPIA sales rose 31% sequentially to $222.7M.
LQDA saw record October patient shipments and 1,300 prescribers amid post-settlement referral disruptions.
Liquidia maintained 94% gross margin and plans to share details on its 2027 revenue outlook in January.
Liquidia Corporation (LQDA - Free Report) emphasized continued YUTREPIA growth and commercial stability during its third-quarter 2026 earnings call, following a global settlement with United Therapeutics that reshaped the drug’s addressable market.
Management highlighted sustained patient demand, expanding prescriber adoption and improving profitability while acknowledging temporary referral disruptions. Executives also outlined plans to strengthen YUTREPIA’s position in pulmonary arterial hypertension (PAH) and advance its clinical pipeline.
Liquidia Addresses Settlement and Market Access
Chief executive officer Roger Jeffs emphasized that the October settlement eliminated the litigation overhang while preserving YUTREPIA’s commercial availability. The company will focus future promotional activities on PAH rather than pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Jeffs clarified that existing PH-ILD patients are not required to discontinue treatment. Management reported no indications that physicians, insurers or specialty pharmacies intend to proactively transition these patients to alternative therapies.
During questions from BofA Securities, chief commercial officer Scott Moomaw described the new physician attestation requirement as a routine prescription-form checkbox. Chief operating officer and chief financial officer Michael Kaseta added that payer coverage remained unchanged.
LQDA Sees Durable Demand Despite Referral Disruption
Jeffs reported that October patient shipments reached their highest monthly level since launch, despite uncertainty surrounding the late-September court ruling and subsequent settlement.
Daily referrals during October exceeded 75% of the third-quarter rate. Jeffs attributed the temporary slowdown to uncertainty among selected prescribing centers and expressed confidence that referral activity would recover.
The prescriber base expanded to approximately 1,300, with more first-time prescribers added in October than September. Meanwhile, over 70% of September prescriptions included a PAH diagnosis, reinforcing management’s emphasis on that market.
Liquidia Highlights Earnings Beat and Operating Leverage
Liquidia reported third-quarter earnings of 80 cents per share against the Zacks Consensus Estimate of 77 cents, representing a 3-cent beat, according to the supplied earnings comparison data.
Quarterly revenues reached $225.3 million, surpassing the Zacks Consensus Estimate of $186.6 million. Revenues increased 314.6% year over year, supported by strong YUTREPIA demand.
Liquidia Corporation Price, Consensus and EPS Surprise
Kaseta highlighted YUTREPIA net product sales of $222.7 million, up 31% sequentially. Adjusted EBITDA increased for the fifth consecutive quarter to $140.5 million, while gross margin remained approximately 94%.
LQDA Management Defers 2027 Revenue Outlook
During an exchange with BTIG, Kaseta indicated that management expects to provide additional information regarding its 2027 revenue outlook in early January, after reviewing further commercial data.
Management emphasized that existing patient demand remained stable despite the litigation-related disruption. Referral-to-patient-start conversion exceeded 87%, providing additional support for the commercial outlook.
In response to H.C. Wainwright, Kaseta explained that recurring prescriptions from existing patients contributed the overwhelming majority of quarterly revenues. More than half of new patients initially received free-drug vouchers, delaying their contribution to paid sales.
Liquidia Advances YUTREPIA and L606 Development
Jeffs outlined continued investment in YUTREPIA studies examining dosing flexibility and broader treatment opportunities. The SPRINT study will evaluate three-times-daily versus four-times-daily dosing in PAH.
Chief medical officer Rajeev Saggar told Jefferies that SPRINT targets a 20% to 25% reduction in pulmonary vascular resistance. Management expects the study to begin in the fourth quarter of 2026.
Meanwhile, L606 development continues across PAH and PH-ILD, with pivotal studies targeting completion in 2029. Liquidia also plans a PH-COPD pivotal study in the second half of 2027, while its RE-WARM Raynaud’s phenomenon study targets primary completion in the first quarter of 2027.
LQDA Focuses on Commercial Execution
Jeffs acknowledged that investors would require continued evidence of commercial performance following the settlement. Management remains focused on growing PAH adoption while maintaining treatment continuity for existing patients.
Executives emphasized that YUTREPIA’s differentiated dosing flexibility remains central to its commercial strategy. Continued referral recovery, patient retention and clinical execution will shape the company’s priorities moving forward.
What Zacks Rank and Style Scores Signal for LQDA
Liquidia currently carries a Zacks Rank #5 (Strong Sell), indicating an unfavorable near-term earnings estimate revision outlook. Its Growth Score of A reflects attractive growth characteristics, while its Value Score of F and Momentum Score of D highlight weaknesses in valuation and price momentum.
The stock’s VGM Score of B indicates favorable combined style characteristics. However, the Zacks framework prioritizes earnings estimate revisions over individual Style Scores, making the unfavorable rank particularly relevant. The Zacks Rank can change as analysts revise their estimates following the latest quarterly results.
View the Zacks #1 Rank List
Image: Bigstock
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
Key Takeaways
Liquidia Corporation (LQDA - Free Report) emphasized continued YUTREPIA growth and commercial stability during its third-quarter 2026 earnings call, following a global settlement with United Therapeutics that reshaped the drug’s addressable market.
Management highlighted sustained patient demand, expanding prescriber adoption and improving profitability while acknowledging temporary referral disruptions. Executives also outlined plans to strengthen YUTREPIA’s position in pulmonary arterial hypertension (PAH) and advance its clinical pipeline.
Liquidia Addresses Settlement and Market Access
Chief executive officer Roger Jeffs emphasized that the October settlement eliminated the litigation overhang while preserving YUTREPIA’s commercial availability. The company will focus future promotional activities on PAH rather than pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Jeffs clarified that existing PH-ILD patients are not required to discontinue treatment. Management reported no indications that physicians, insurers or specialty pharmacies intend to proactively transition these patients to alternative therapies.
During questions from BofA Securities, chief commercial officer Scott Moomaw described the new physician attestation requirement as a routine prescription-form checkbox. Chief operating officer and chief financial officer Michael Kaseta added that payer coverage remained unchanged.
LQDA Sees Durable Demand Despite Referral Disruption
Jeffs reported that October patient shipments reached their highest monthly level since launch, despite uncertainty surrounding the late-September court ruling and subsequent settlement.
Daily referrals during October exceeded 75% of the third-quarter rate. Jeffs attributed the temporary slowdown to uncertainty among selected prescribing centers and expressed confidence that referral activity would recover.
The prescriber base expanded to approximately 1,300, with more first-time prescribers added in October than September. Meanwhile, over 70% of September prescriptions included a PAH diagnosis, reinforcing management’s emphasis on that market.
Liquidia Highlights Earnings Beat and Operating Leverage
Liquidia reported third-quarter earnings of 80 cents per share against the Zacks Consensus Estimate of 77 cents, representing a 3-cent beat, according to the supplied earnings comparison data.
Quarterly revenues reached $225.3 million, surpassing the Zacks Consensus Estimate of $186.6 million. Revenues increased 314.6% year over year, supported by strong YUTREPIA demand.
Liquidia Corporation Price, Consensus and EPS Surprise
Liquidia Corporation price-consensus-eps-surprise-chart | Liquidia Corporation Quote
Kaseta highlighted YUTREPIA net product sales of $222.7 million, up 31% sequentially. Adjusted EBITDA increased for the fifth consecutive quarter to $140.5 million, while gross margin remained approximately 94%.
LQDA Management Defers 2027 Revenue Outlook
During an exchange with BTIG, Kaseta indicated that management expects to provide additional information regarding its 2027 revenue outlook in early January, after reviewing further commercial data.
Management emphasized that existing patient demand remained stable despite the litigation-related disruption. Referral-to-patient-start conversion exceeded 87%, providing additional support for the commercial outlook.
In response to H.C. Wainwright, Kaseta explained that recurring prescriptions from existing patients contributed the overwhelming majority of quarterly revenues. More than half of new patients initially received free-drug vouchers, delaying their contribution to paid sales.
Liquidia Advances YUTREPIA and L606 Development
Jeffs outlined continued investment in YUTREPIA studies examining dosing flexibility and broader treatment opportunities. The SPRINT study will evaluate three-times-daily versus four-times-daily dosing in PAH.
Chief medical officer Rajeev Saggar told Jefferies that SPRINT targets a 20% to 25% reduction in pulmonary vascular resistance. Management expects the study to begin in the fourth quarter of 2026.
Meanwhile, L606 development continues across PAH and PH-ILD, with pivotal studies targeting completion in 2029. Liquidia also plans a PH-COPD pivotal study in the second half of 2027, while its RE-WARM Raynaud’s phenomenon study targets primary completion in the first quarter of 2027.
LQDA Focuses on Commercial Execution
Jeffs acknowledged that investors would require continued evidence of commercial performance following the settlement. Management remains focused on growing PAH adoption while maintaining treatment continuity for existing patients.
Executives emphasized that YUTREPIA’s differentiated dosing flexibility remains central to its commercial strategy. Continued referral recovery, patient retention and clinical execution will shape the company’s priorities moving forward.
What Zacks Rank and Style Scores Signal for LQDA
Liquidia currently carries a Zacks Rank #5 (Strong Sell), indicating an unfavorable near-term earnings estimate revision outlook. Its Growth Score of A reflects attractive growth characteristics, while its Value Score of F and Momentum Score of D highlight weaknesses in valuation and price momentum.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock’s VGM Score of B indicates favorable combined style characteristics. However, the Zacks framework prioritizes earnings estimate revisions over individual Style Scores, making the unfavorable rank particularly relevant. The Zacks Rank can change as analysts revise their estimates following the latest quarterly results.